alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY INFORMATION EXTRACTED FROM 2ND QUARTER 10-QSB AND
IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               JUN-30-1998
<CASH>                                         193,401
<SECURITIES>                                         0
<RECEIVABLES>                                2,184,170
<ALLOWANCES>                                         0
<INVENTORY>                                  1,572,151
<CURRENT-ASSETS>                             4,098,675
<PP&E>                                      21,713,987
<DEPRECIATION>                              (7,778,232)
<TOTAL-ASSETS>                              44,780,296
<CURRENT-LIABILITIES>                        4,147,071
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     1,126,801
<OTHER-SE>                                   9,856,708
<TOTAL-LIABILITY-AND-EQUITY>                44,780,296
<SALES>                                              0
<TOTAL-REVENUES>                            12,553,875
<CGS>                                        5,149,891
<TOTAL-COSTS>                                6,710,113
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           1,615,743
<INCOME-PRETAX>                               (919,244)
<INCOME-TAX>                                     5,000
<INCOME-CONTINUING>                           (924,244)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (924,244)
<EPS-PRIMARY>                                    (0.21)
<EPS-DILUTED>                                        0
        

</TABLE>
Case 1:07-cv-03384-JCF Document 12 Filed 07/09/2007 Page 1 of 3
Case 1:07-cv-03384-JCF Document 12 Filed 07/09/2007 Page 2 of 3
Case 1:07-cv-03384-JCF Document 12 Filed 07/09/2007 Page 3 of 3
```

[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[S. 1662 Introduced in Senate (IS)]

<DOC>

116th CONGRESS
  1st Session
                                S. 1662

     To establish an annual fee applicable to opioid manufacturers.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                 May 23 (legislative day, May 22), 2019

  Mr. Merkley introduced the following bill; which was read twice and 
  referred to the Committee on Health, Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL

 
     To establish an annual fee applicable to opioid manufacturers.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Opioid Treatment Surge Act''.

SEC. 2. ANNUAL FEE.

    (a) In General.--For each of the 10 calendar years immediately 
proceeding the date of enactment of this Act, the Secretary of Health 
and Human Services shall assess a fee against each prescription drug 
manufacturer that, at any time during the period beginning on January 
1, 1999, and ending on the calendar year immediately preceding the year 
in which the fee is assessed, manufactured any opioid drug (other than 
a drug described in subsection (b)). Such fee, with respect to such a 
manufacturer, shall be in an amount, as determined by such Secretary, 
that bears the same relationship to $2,000,000,000 as the market share 
of any such opioid drugs manufactured by such manufacturer during the 
period for which the fee is being assessed bears to the total market 
for opioid drugs (excluding such drugs described in subsection (b)) 
during such period.
    (b) Exceptions.--The fee described in subsection (a) shall not 
apply with respect to any opioid drug used exclusively for the 
treatment of--
            (1) opioid addiction, as part of a medically assisted 
        treatment effort; or
            (2) cancer or hospice patients.
    (c) Transfers To Block Grant Programs.--For each year that the 
Secretary of Health and Human Services assesses fees under subsection 
(a), the Secretary of the Treasury shall transfer from the general fund 
of the Treasury to the Secretary of Health and Human Services an amount 
equal to the amount of such fees, for purposes of carrying out the 
substance abuse prevention and treatment block grant under subpart II 
of part B of title XIX of the Public Health Service Act (42 U.S.C. 
300x-21 et seq.).
                                 <all>
```
#### MANLY v. PENNY

No. 109 PC.

Case below: 35 N.C. App. 774.

Petition by plaintiff for discretionary review under G.S. 7A-31 denied 6 June 1978.
#### STATE v. HEARD and JONES

No. 125 PC.

Case below: 20 N.C. App. 124.

Petition by defendants Heard and Jones for writ of cer-tiorari to North Carolina Court of Appeals denied 5 February 1974. Motion of Attorney General to dismiss appeal of defendant Jones denied 5 February 1974.
#### STATE v. DUERS

No. 131PC

Case below: 49 N.C. App. 282

Petition by defendant for discretionary review under G.S. 7A-31 denied 4 March 1981.
Case 1:06-cv-15147-AKH Document 3 Filed 12/08/2006 Page 1 of 1
EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Section 1350 of Chapter 63 of Title
18 of the United States Code), each of the undersigned officers of Kreisler Manufacturing Corporation (the Company) does hereby certify with respect to the Quarterly Report of the Company on Form 10-QSB for the period ended
December 31, 2006 (the Report) that:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



|                        |  |                        
|----------------------- |  | -----------------------
|Date: February 14, 2007 |  | /s/ Michael D. Stern   
|                        |  | Michael D. Stern       
|                        |  | Chief Executive Officer
|                        | 
|Date: February 14, 2007 |  | /s/ Edward A. Stern    
|                        |  | Edward A. Stern        
|                        |  | Chief Financial Officer

The foregoing certification is being furnished solely pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002 (Section 1350 of Chapter 63 of Title 18 of the United States Code) and is not being filed as part of the Report or as a separate disclosure document.
Case 7:04-cv-08928-KMK-LMS     Document 40      Filed 05/03/2007     Page 1 of 3

Case 7:04-cv-08928-KMK-LMS     Document 40      Filed 05/03/2007     Page 2 of 3

Case 7:04-cv-08928-KMK-LMS     Document 40      Filed 05/03/2007     Page 3 of 3
##### 



Exhibit 32.1


CERTIFICATION PURSUANT TO


18 U.S.C. §1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002






| |                                                                                                                                                                 
| | ----------------------------------------------------------------------------------------------------------------------------------------------------------------
| | (1) The Report fully complies with the requirements of
    Section 13(a) or 15(d) of the Securities Exchange Act of
    1934; and                               
|
| | (2) The information contained in the Report fairly
    presents, in all material respects, the financial condition and
    results of operations of the Company.



| |                                      
| | -------------------------------------
| | /s/ Mack V. Traynor, III             
| |                                      
| | Mack V. Traynor, III                 
| | Chief Executive Officer and President








|  |                                                                                                                                                                                                                                    
|- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|* | A signed original of this written statement required by
    Section 906 has been provided to HEI, Inc. and will be
    retained by HEI, Inc. and furnished to the Securities and
    Exchange Commission or its staff upon request.
**EXHIBIT 23****CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**We consent to the incorporation by reference in Registration Statement No. 333-108790 on Form S-8,Registration Statement No. 333-62566 on Form S-8, RegistrationStatement No. 333-53449 on Form S-8, and Registration Statement No.333-104732 on Form S-8 of our report dated December 21, 2005,relating to the consolidated financial statements of American PacificCorporation, appearing in this Annual Report onForm 10-K of American Pacific Corporation for the year ended September 30, 2005./s/ DELOITTE & TOUCHE LLP
**Exhibit 99.1**

**CERTIFICATION PURSUANT TO****18 U.S.C. SECTION 1350.****AS ADOPTED PURSUANT TO****SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

            In connection with the Annual Report of PharmaKinetics Laboratories, Inc. (the “Company”) on Form 10-K/A for the year ended June 30, 2002 as filed with the Securities and Exchange Commission on the date hereof (the”Report”), I, James M. Wilkinson, II, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

|   | (1)    |   | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and                               |
|--------|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |   |
|   | (2)    |   | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |

|                                                      |   |        |
|------------------------------------------------------|--------|--------|
| /s/ James M. Wilkinson, II, Ph.D.                    |   |   |
| James M. Wilkinson, II, Ph.D.                        |   |   |
| President and Chief Executive OfficerAugust 12, 2002 |   |   |
Case 1:06-cv-15080-AKH Document 1 Filed 12/08/2006 Page 1 of 13
Case 1:06-cv-15080-AKH Document 1 Filed 12/08/2006 Page 2 of 13
Case 1:06-cv-15080-AKH Document 1 Filed 12/08/2006 Page 3 of 13
Case 1:06-cv-15080-AKH Document 1 Filed 12/08/2006 Page 4 of 13
Case 1:06-cv-15080-AKH Document 1 Filed 12/08/2006 Page 5 of 13
Case 1:06-cv-15080-AKH Document 1 Filed 12/08/2006 Page 6 of 13
Case 1:06-cv-15080-AKH Document 1 Filed 12/08/2006 Page 7 of 13
Case 1:06-cv-15080-AKH Document 1 Filed 12/08/2006 Page 8 of 13
Case 1:06-cv-15080-AKH Document 1 Filed 12/08/2006 Page 9 of 13
Case 1:06-cv-15080-AKH Document 1 Filed 12/08/2006 Page 10 of 13
Case 1:06-cv-15080-AKH Document 1 Filed 12/08/2006 Page 11 of 13
Case 1:06-cv-15080-AKH Document 1 Filed 12/08/2006 Page 12 of 13
Case 1:06-cv-15080-AKH Document 1 Filed 12/08/2006 Page 13 of 13
Case 1:06-cv-15022-AKH Document 4 Filed 12/08/2006 Page 1 of 1
EXHIBIT A

Case 7:07-cv-03302-KMK-LMS Document 42-2 Filed 07/09/2007 Page 1 of 7
Case 7:07-cv-03302-KMK-LMS Document 42-2 Filed 07/09/2007 Page 2 of 7
Case 7:07-cv-03302-KMK-LMS Document 42-2 Filed 07/09/2007 Page 3 of 7
Case 7:07-cv-03302-KMK-LMS Document 42-2 Filed 07/09/2007 Page 4 of 7
Case 7:07-cv-03302-KMK-LMS Document 42-2 Filed 07/09/2007 Page 5 of 7
Case 7:07-cv-03302-KMK-LMS Document 42-2 Filed 07/09/2007 Page 6 of 7
Case 7:07-cv-03302-KMK-LMS Document 42-2 Filed 07/09/2007 Page 7 of 7
[Federal Register Volume 70, Number 219 (Tuesday, November 15, 2005)]
[Notices]
[Page 69360]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-22635]


=======================================================================
-----------------------------------------------------------------------

NATIONAL SCIENCE FOUNDATION


Proposal Review Panel for Materials Research; Notice of Meeting

    In accordance with the Federal Advisory Committee Act (Pub. L. 92-
463 as amended), the National Science Foundation announces the 
following meeting:

    Name: Proposal Review Panel for Materials Research (DMR) 
<greek-i>1203.
    Dates and Times: December 8, 2005; 7:45 a.m.-8 p.m. (open: 8:15-
11:45, 12:45-3:30, 5-6; closed: 3:30-5, 6-8).
    December 9, 2005; 8 a.m.-3 p.m. (open 9-9:45).
    Place: Columbia University, New York, NY.
    Type of Meeting: Part open.
    Contact Person: Dr. Maija M. Kukla, Program Director, Materials 
Research Science and Engineering Centers, Division of Materials 
Research, Room 1065, National Science Foundation, 4201 Wilson 
Boulevard, Arlington, VA 22230, Telephone (703) 292-4940.
    Purpose of Meeting: To provide advice and recommendations 
concerning progress of Materials Research Science and Engineering 
Center.
    Agenda: December 8, 2005--Closed to brief site visit panel.
    December 9, 2005--Open for Directors overview of Materials 
Research Science and Engineering Center and presentations. Closed to 
review and evaluate progress of Materials Research Science and 
Engineering Center.
    Reason for Closing: The work being reviewed may include 
information of a proprietary or confidential nature, including 
technical information; financial data, such as salaries and personal 
information concerning individuals associated with the proposals. 
These matters are exempt under 5 U.S.C. 552b(c), (4) and (6) of the 
Government in the Sunshine Act.

    Dated: November 8, 2005.
Susanne Bolton,
Committee Management Officer.
[FR Doc. 05-22635 Filed 11-14-05; 8:45 am]
BILLING CODE 7555-01-M
```

[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[S. 1654 Introduced in Senate (IS)]

<DOC>

116th CONGRESS
  1st Session
                                S. 1654

To amend the Internal Revenue Code of 1986 to provide authority to add 
          additional vaccines to the list of taxable vaccines.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                 May 23 (legislative day, May 22), 2019

  Mr. Casey (for himself, Mr. Isakson, Mr. Menendez, Mr. Portman, Mr. 
Cardin, and Mr. Cassidy) introduced the following bill; which was read 
             twice and referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
To amend the Internal Revenue Code of 1986 to provide authority to add 
          additional vaccines to the list of taxable vaccines.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Vaccine Access Improvement Act of 
2019''.

SEC. 2. ADDITION OF NEW VACCINES TO LIST OF TAXABLE VACCINES.

    (a) In General.--Section 4132(a)(1) of the Internal Revenue Code of 
1986 is amended by adding at the end the following new subparagraph:
                    ``(Q) Any vaccine which is not described in any 
                other subparagraph of this paragraph and which is 
                included on the Vaccine Injury Table under section 2114 
                of the Public Health Service Act.''.
    (b) Notification.--Not later than 30 days after the Secretary of 
Health and Human Services adds a vaccine to the Vaccine Injury Table 
pursuant of section 2114 of the Public Health Service Act (42 U.S.C. 
300aa-14), the Secretary shall notify the Secretary of the Treasury, 
the Committee on Health, Education, Labor, and Pensions of the Senate, 
the Committee on Finance of the Senate, the Committee on Energy and 
Commerce of the House of Representatives, and the Committee on Ways and 
Means of the House of Representatives of such designation.
    (c) Effective Date.--
            (1) Sales, etc.--The amendment made by subsection (a) shall 
        apply to sales and uses on or after the date on which the 
        Secretary of Health and Human Services lists any new vaccine 
        pursuant to section 2114 of the Public Health Service Act (42 
        U.S.C. 300aa-14) for purposes of compensation for any vaccine-
        related injury or death through the Vaccine Injury Compensation 
        Trust Fund.
            (2) Deliveries.--For purposes of paragraph (1) and section 
        4131 of the Internal Revenue Code of 1986, in the case of sales 
        on or before the effective date described in such paragraph for 
        which delivery is made after such date, the delivery date shall 
        be considered the sale date.
                                 <all>
```
EXHIBIT 23.1

INDEPENDENT AUDITORS' CONSENT

We consent to the incorporation by reference in Registration Statement
Nos. 33-22990, 33-38210, 33-51588 and 33-61624 on Forms S-3 and in
Registration Statement Nos. 2-83273, 2-98984, 33-27288, 33-38209
and 33-86078 on Forms S-8 of Jackpot Enterprises, Inc. of our report
dated August 1, 1997, appearing in this Annual Report on Form 10-K of
Jackpot Enterprises, Inc. for the year ended June 30, 1997.

/s/ Deloitte & Touche LLP

DELOITTE & TOUCHE LLP


Las Vegas, Nevada
September 22, 1997
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from 
Century Properties Fund XVI 1997 Year-End 10-KSB and is qualified
in its entirety by reference to such 10-KSB filing.
</LEGEND>
<CIK> 0000351931         
<NAME> CENTURY PROPERTIES FUND XVI
<MULTIPLIER> 1,000     
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-END>                               DEC-31-1997   
<CASH>                                             459
<SECURITIES>                                         0
<RECEIVABLES>                                      307
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0<F1>
<PP&E>                                          14,947
<DEPRECIATION>                                   7,303   
<TOTAL-ASSETS>                                   8,787   
<CURRENT-LIABILITIES>                                0<F1>
<BONDS>                                          7,422     
<PREFERRED-MANDATORY>                                0     
<PREFERRED>                                          0  
<COMMON>                                             0
<OTHER-SE>                                         894    
<TOTAL-LIABILITY-AND-EQUITY>                     8,787    
<SALES>                                              0
<TOTAL-REVENUES>                                 2,867    
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                 3,024    
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 620    
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     (157)     
<EPS-PRIMARY>                                   (1.12)<F2>
<EPS-DILUTED>                                        0
<FN>
<F1>Registrant has an unclassified balance sheet.
<F2>Multiplier is 1.
</FN>
        


</TABLE>
##### 



EXHIBIT 31.1
 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
  1.
    
    I have reviewed this annual report on Form 10-K of American Pacific
Corporation, a Delaware corporation (the registrant);2.
    
    Based on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact necessary in order to make the
statements made, in light of the circumstances under which such statements were made,
not misleading with respect to the period covered by this report;3.
    
    Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and
for, the periods presented in this report;4.
    
    The registrants other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
 (a)
    
    Designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;(b)
    
    Evaluated the effectiveness of the registrants disclosure controls and
procedures and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period covered by this
report based on such evaluation; and(c)
    
    Disclosed in this report any change in the registrants internal
control over financial reporting that occurred during the registrants most recent
fiscal quarter (the registrants fourth fiscal quarter in the case of an annual
report) that has materially affected, or is reasonably likely to materially affect,
the registrants internal control over financial reporting; and
 5.
    
    The registrants other certifying officer and I have disclosed, based on our
most recent evaluation of internal control over financial reporting, to the
registrants auditors and the audit committee of registrants board of directors (or
persons performing the equivalent function):
 (a)
    
    All significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are reasonably likely
to adversely effect the registrants ability to record, process, summarize and
report financial information; and(b)
    
    Any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrants internal control over
financial reporting.
 Date: December 22, 2005
    
    By:
    
    /s/ JOHN R. GIBSONJohn R. Gibson, Principal Executive Officer